- Home
- PRFX vs CDT Comparison
PRFX vs CDT Comparison
Compare PRFX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- CDT
- Stock Information
- Founded
- PRFX 2007
- CDT 2019
- Country
- PRFX Israel
- CDT United States
- Employees
- PRFX N/A
- CDT N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- CDT Health Care
- Exchange
- PRFX Nasdaq
- CDT Nasdaq
- Market Cap
- PRFX 2.8M
- CDT 2.3M
- IPO Year
- PRFX 2020
- CDT N/A
- Fundamental
- Price
- PRFX $1.25
- CDT $3.54
- Analyst Decision
- PRFX Hold
- CDT
- Analyst Count
- PRFX 1
- CDT 0
- Target Price
- PRFX N/A
- CDT N/A
- AVG Volume (30 Days)
- PRFX 187.7K
- CDT 646.8K
- Earning Date
- PRFX 11-14-2025
- CDT 11-13-2025
- Dividend Yield
- PRFX N/A
- CDT N/A
- EPS Growth
- PRFX N/A
- CDT N/A
- EPS
- PRFX N/A
- CDT N/A
- Revenue
- PRFX N/A
- CDT N/A
- Revenue This Year
- PRFX N/A
- CDT N/A
- Revenue Next Year
- PRFX N/A
- CDT N/A
- P/E Ratio
- PRFX N/A
- CDT N/A
- Revenue Growth
- PRFX N/A
- CDT N/A
- 52 Week Low
- PRFX $1.20
- CDT $3.40
- 52 Week High
- PRFX $16.63
- CDT $2,198.40
- Technical
- Relative Strength Index (RSI)
- PRFX 41.76
- CDT 71.27
- Support Level
- PRFX $1.22
- CDT $3.41
- Resistance Level
- PRFX $1.37
- CDT $4.50
- Average True Range (ATR)
- PRFX 0.09
- CDT 0.29
- MACD
- PRFX -0.01
- CDT 0.38
- Stochastic Oscillator
- PRFX 7.15
- CDT 76.06
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.